Please ensure Javascript is enabled for purposes of website accessibility

Why Alkermes Is Sinking Today

By Brian Feroldi - Feb 22, 2018 at 3:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tumble after the company receives an analyst downgrade. Here's what investors need to know.

What happened

In response to receiving an analyst downgrade, shares of Alkermes (ALKS -1.65%), a commercial-stage biopharma focused on diseases of the central nervous system, fell 11% as of 3:15 p.m. EST on Thursday.

So what

An analyst at Jeffries downgraded shares of Alkermes today to "hold" from "buy." The logic behind the downgrade was that shares are "fairly valued and factor significant value for the late-stage pipeline."

Business man looking worried at his laptop

Image source: Getty Images.

Specifically, the analyst is worried that ALKS-4230 -- which is an Alkermes compound that is currently being tested as a treatment for various types of cancer -- might not be as effective of a treatment as Nektar Therapeutics' (NKTR -4.04%) NKTR-214, which is another pipeline cancer compound that could compete with ALKS-4230 someday. 

When combined with the recent run-up in Alkermes' stock thanks to good-looking earnings, the analyst felt that downgrading the stock made sense.

Now what

Short-term price movements aside, this Fool thinks that Alkermes bulls still have plenty of positives to look forward to in 2018. The company is slated to hear from regulators on two drug submissions and could also earn a big milestone payment if a third is sent off for review. There are also a number of clinical readouts that are slated to be released through the year, not to mention the continued ramp in sales of Vivitrol and Aristada.

All in all, I continue to agree with Alkermes CFO James Frates that Alkermes is set up to have a "transformative" 2018. If you feel the same way, then today's downward slide shouldn't bother you one bit.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
$29.79 (-1.65%) $0.50
Nektar Therapeutics Stock Quote
Nektar Therapeutics
$3.80 (-4.04%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.